Clinical trials: Vision Therapy
Ocular Graft-versus-host Disease
RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
rhPRG4-GVHD-001 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with moderate to severe dry eye secondary to chronic GVHD.
- Trial name
- NCT06495307
- Testing
- rhPRG4
- Where
- 2 sites in Australia
- Volunteers
- 3 people
- Sponsor
- Lubris Bio Pty Ltd
Non-exudative (Dry) Age-related Macular Degeneration (AMD)
HELP Therapy for Dry AMD
This is an open-label, single center clinical investigation to evaluate the efficacy and safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a treatment for non-exudative (dry) Age-related…
- Trial name
- HELPuc (NCT01840683)
- Testing
- H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- B.Braun Avitum AG
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Seasonal Allergic Rhinitis
A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine
The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.
- Trial name
- NCT01108783
- Testing
- Bilastine, Desloratadine
- Volunteers
- 720 people
- Sponsor
- Faes Farma, S.A.
Cataract in Inflammatory Ocular Disorders
A Clinical Study to Assess the Efficacy and Safety of SED80 for Use in Cataract Surgery
Patients at least 40 years of age who are undergoing cataract surgery will be randomized to receive treatment with one of four groups of dexamethasone ophthalmic suspension or placebo eye drops to determine if the drops decrease…
- Trial name
- NCT04711213
- Testing
- Dexamethasone Dose 1, Dexamethasone Dose 2
- Where
- El Salvador
- Volunteers
- 60 people
- Sponsor
- iDrop, Inc.
Retinal Disease, Macular Degeneration
Stem Cell Ophthalmology Treatment Study
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease. http://mdstemcells.com/scots-ii/
- Conditions
- Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease
- Trial name
- SCOTS (NCT01920867)
- Testing
- RB (Retrobulbar), ST (Subtenon), IV (Intravenous)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- MD Stem Cells
Optic, Atrophy, Hereditary, Leber
Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation
The goal of this clinical trial is to assess the effectiveness of GS010, a gene therapy, in improving the visual outcome in participants with Leber Hereditary Optic Neuropathy (LHON) due to the G11778A ND4 mitochondrial mutation…
- Trial name
- RESCUE (NCT02652767)
- Testing
- GS010
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 39 people
- Sponsor
- GenSight Biologics
Open Angle Glaucoma, Ocular Hypertension
SYL040012, Treatment for Open Angle Glaucoma
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28…
- Trial name
- SYLTAG (NCT02250612)
- Testing
- 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran)
- Where
- 21 sites in United States, Estonia and 2 more
- Volunteers
- 184 people
- Sponsor
- Sylentis, S.A.
Infection, Human Immunodeficiency Virus I, HIV Infection
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
A 48-week study to investigate the safety and effectiveness of a new compact formulation of two already FDA-approved anti-HIV drugs in subjects who have already been receiving treatment for their HIV infection.
- Trial name
- NCT00044577
- Testing
- abacavir/lamivudine, abacavir, lamivudine
- Where
- 76 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- ViiV Healthcare
Glaucoma
COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)
A study to evaluate the effect of the 12-week treatment with timolol/dorzolamide combination eyedrops (COSOPT) on decrease in intraocular pressure (IOP) at 2 hours after the study drug administration
- Trial name
- NCT00832377
- Testing
- timolol/dorzolamide combination
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Intraocular Melanoma, Melanoma (Skin)
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00324727
- Testing
- melphalan, regional chemotherapy, systemic chemotherapy
- Where
- 12 sites in United States
- Volunteers
- 93 people
- Sponsor
- Delcath Systems Inc.
Ocular Inflammation, Infection Associated Blepharitis
Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection
To evaluate the efficacy and safety of fixed combination of azithromycin 1.5% + 0.5% Loteprednol eye drops for the treatment of ocular inflammation and infection associated bacterial blepharitis and / or keratitis and / or…
- Conditions
- Ocular Inflammation, Infection Associated Blepharitis, Keratitis, Conjunctivitis, Bacterial
- Trial name
- NCT01721694
- Testing
- azithromycin 1.5% + Loteprednol 0,5% (separately)
- Where
- Brazil
- Sponsor
- Adapt Produtos Oftalmológicos Ltda.
Glaucoma, Ocular Hypertension
An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®
The purpose of this study is evaluate effects of TRAVATAN® versus LUMIGAN® on intraocular pressure (IOP) and ocular surface and inflammatory biomarkers.
- Trial name
- NCT01664039
- Testing
- Travoprost 0.004% ophthalmic solution, Bimatoprost 0.01% ophthalmic solution
- Volunteers
- 104 people
- Sponsor
- Alcon Research
Cataract
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)
A Phase 3, Prospective, Randomized, Double-masked, Placebo-controlled, Parallel-design, Multicenter Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated with Cataract Surgery
- Trial name
- NCT05550363
- Testing
- Dexycu
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Glaucoma, Ocular Hypertension
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle glaucoma.
- Trial name
- NCT01263444
- Testing
- Brinzolamide 1% / timolol 0.5% Fixed Combination, Habitual prostaglandin monotherapy
- Volunteers
- 47 people
- Sponsor
- Alcon Research
Achromatopsia
Gene Therapy for Achromatopsia (CNGA3)
A clinical trial of adeno-associated virus vector (AAV) CNGA3 retinal gene therapy for patients with achromatopsia
- Trial name
- CNGA3 (NCT03758404)
- Testing
- adeno-associated virus vector AAV- CNGA3
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 11 people
- Sponsor
- MeiraGTx UK II Ltd
Cataract
Nepafenac Compared to Placebo for Ocular Pain and Inflammation
The purpose of this study was to demonstrate that Nepafenac Ophthalmic Suspension, 0.1% is superior to Nepafenac Vehicle (placebo) for the prevention and treatment of ocular inflammation and pain associated with cataract surgery…
- Trial name
- NCT01426854
- Testing
- Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle Ophthalmic Solution
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)
This study will test the hypothesis that preservative-free tafluprost (MK-2452) is non-inferior to preservative-free timolol maleate with respect to the diurnal intraocular pressure (IOP) change from baseline after 4 weeks of…
- Trial name
- NCT01254604
- Testing
- Preservative-Free Tafluprost or vehicle, Preservative-Free Timolol maleate
- Volunteers
- 190 people
- Sponsor
- Merck Sharp & Dohme LLC
Dry Eye Disease
Study on Safety and Performance of an Artificial Tear in Dry Eye Treatment in Subjects With Ocular Surface Inflammation
This is post-market study to evaluate the safety and efficacy of MDI - 101 a novel tear substitute for the treatment of dry eye (DE) in subjects with evidence of inflammation of the ocular surface.
- Trial name
- NCT04633863
- Testing
- Artificial tear MDI - 101
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- MD Italy
Age-related Macular Degeneration (AMD)
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
This was the cross-sectional study to assess the period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019.
- Trial name
- NCT05146687
- Testing
- Aflibercept, Ranibizumab, Bevacizumab
- Where
- United States
- Volunteers
- 369,600 people
- Sponsor
- Novartis Pharmaceuticals